XNAS · EXEL
+1.76% · +$0.9900 · Vol 2.5M
Market closed · last close 4:00 PM ET · price as of 16:05:39 ET
Exelixis Inc

Exelixis Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$57.10
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is EXEL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for EXEL are being assembled.
About Exelixis Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2000
Employees
1K
Country
US

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$56.02
Day high
$57.42
Day low
$56.02
Previous close
$56.11
52W high
$57.42
-0.56% from high
52W low
$51.50
95% of range
Market cap
$14.1B
P/E
21.31×
EPS
$2.68
Shares out
251.4M
Volume
2.5M
VWAP
$57.00
Price history computed in-house
1W
+2.73%
1M
+6.79%
SMA 50 $54.04 · above
SMA 200 $54.04 · above
52W position 95%
Veridion warehouse edge

Warehouse intelligence for EXEL.

Veridion Score
70
0: 441: 472: 683: 704: 675: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

EXEL insider activity

Exelixis Inc

Score
Coverage building
Pressure
Net selling
Filings
57
Buys / sells
10 / 47
Net value
-$76.2M
Insiders
14
Named filers
EG
Eckhardt Sue Gail
Insider
Leadership
WL
WYSZOMIERSKI JACK L
Insider
Leadership
AD
Aftab Dana
Insider
Leadership
Cluster

2 insiders bought in the last 90 days

Net pressure

Net selling: -$76.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-032026-06-01Eckhardt Sue GailInsidersell$50.149,81216,079$492KSEC Form 4
2026-06-032026-06-01WYSZOMIERSKI JACK LInsidersell$50.553,925284,384$198KSEC Form 4
2026-05-282026-05-26Aftab DanaInsidersell$50.3543,451594,741$2.2MSEC Form 4
2026-05-222026-05-20Haley Patrick J.Insidersell$49.8132,110357,638$1.6MSEC Form 4
2026-05-192026-05-18Hefti BrendaInsidersell$50.216,625106,762$333KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 52 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

EXEL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EXEL in this window.
Lobbying spend

EXEL lobbying filings, year to date.

Registered lobbying filings matched to Exelixis Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EXEL in this window.
Latest news · EXEL
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for EXEL.
Options
Sovereign unlock shows live options positioning for EXEL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.